



HAL
open science

A muscle-specific MURF1-E2 network requires stabilization of MURF1-E2 complexes by telethonin, a newly identified substrate

Cécile Polge, Stéphanie Cabantous, Christiane Deval, Agnès Claustre, Catherine Bouchenot, Julien Aniort, Daniel Béchet, Lydie Combaret, Didier Attaix, Daniel Taillandier

► To cite this version:

Cécile Polge, Stéphanie Cabantous, Christiane Deval, Agnès Claustre, Catherine Bouchenot, et al.. A muscle-specific MURF1-E2 network requires stabilization of MURF1-E2 complexes by telethonin, a newly identified substrate. SFBBM – 8ème Colloque Protéolyse Cellulaire, Oct 2018, La Grande-Motte, France. hal-02952775

HAL Id: hal-02952775

<https://hal.inrae.fr/hal-02952775>

Submitted on 29 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A MUSCLE-SPECIFIC MURF1-E2 NETWORK REQUIRES STABILIZATION OF MURF1-E2 COMPLEXES BY TELETHONIN, A NEWLY IDENTIFIED SUBSTRATE

Cécile Polge (1), Stéphanie Cabantous (2,3), Christiane Deval (1), Agnès Claustre (1), Catherine Bouchenot (2,3), Julien Anriot (1,4), Daniel Béchet (1), Lydie Combaret (1), Didier Attaix (1), Daniel Taillandier (1)

(1) Université Clermont Auvergne, INRA, UNH, Unité de Nutrition Humaine, CRNH Auvergne, F-63000 Clermont-Ferrand, France.

(2) INSERM UMR1037, Cancer Research Center of Toulouse, Toulouse, France.

(3) Université Paul Sabatier, Toulouse, France.

(4) Service de Néphrologie Réanimation Médicale, Pôle Respiratoire, Endocrinologie-Diabétologie, Urologie, Néphrologie-Dialyse, Nutrition Clinique, Infectiologie, Réanimation Médicale, Hygiène Hospitalière (REUNNIRH), Clermont-Ferrand, France.

Muscle wasting is observed in the course of many diseases and also during physiological conditions (disuse, aging). Skeletal muscle mass is largely controlled by the ubiquitin-proteasome system and thus by the ubiquitinating enzymes (E2s and E3s) that target substrates for subsequent degradation. MuRF1 is the only E3 ubiquitin ligase known to target contractile proteins (α -actin, myosins) during catabolic situations (1,2). MuRF1 knock-out partially protected skeletal muscles from atrophy in denervated or immobilized animals (3) MuRF1 is therefore a putative target for preventing muscle wasting. However, MuRF1 depends on E2 ubiquitin conjugating enzymes for ubiquitin chain formation on the substrates.

We focused on 14 E2 enzymes that are either expressed in skeletal muscle or up-regulated during atrophying conditions (4). In this work, we demonstrated that only highly sensitive and complementary interactomic approaches (Surface Plasmon Resonance, Yeast three-Hybrid and split-GFP) allowed the identification of MuRF1 E2 partners. Five E2 enzymes physically interacted with MuRF1, namely E2E1, E2G1, E2J1, E2J2 and E2L3. Moreover, we demonstrated that MuRF1-E2E1 and MuRF1-E2J1 interactions are facilitated by telethonin, a newly identified MuRF1 substrate. We next showed that the 5 identified E2s functionally interacted with MuRF1 since, in contrast to the non-interacting E2D2, their co-expression in HEK293T cells with MuRF1 led to increased telethonin degradation. Finally, we showed that telethonin governed the affinity between MuRF1 and E2E1 or E2J1 (5). We are currently studying the capacity of E2-MuRF1 duos to target the main contractile proteins (actin, myosin heavy chains, ...) both *in vitro* and *in vivo*.

We report here the first MuRF1-E2s network, which may prove valuable for deciphering the precise mechanisms involved in the atrophying muscle program and for proposing new therapeutical approaches.

Reference(s)

(1) Polge C, Heng AE, Jarzaguet M, Ventadour S, Claustre A, Combaret L, Béchet D, Matondo M, Uttenweiler-Joseph S, Monsarrat B, Attaix D, Taillandier D. Muscle actin is polyubiquitinated *in vitro* and *in vivo* and targeted for breakdown by the E3 ligase MuRF1. *FASEB J*. 2011 Nov;25(11):3790-802. doi: 10.1096/fj.11-180968.

(2) Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. *Cell Metab*. 2007 Nov;6(5):376–85.

(3) Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science*. 2001 Nov 23;294(5547):1704–8.

(4) Polge C, Leulmi R, Jarzaguet M, Claustre A, Combaret L, Béchet D, Heng AE, Attaix D, Taillandier D. UBE2B is implicated in myofibrillar protein loss in catabolic C2C12 myotubes. *J Cachexia Sarcopenia Muscle*. 2016 Jun;7(3):377-87. doi: 10.1002/jcsm

(5) Polge C, Cabantous S, Deval C, Claustre A, Hauvette A, Bouchenot C, Anriot J, Béchet D, Combaret L, Attaix D, Taillandier D. A muscle-specific MuRF1-E2 network requires stabilization of MuRF1-E2 complexes by telethonin, a newly identified substrate. *J Cachexia Sarcopenia Muscle*. 2017 doi.org/10.1002/jcsm.12249

Keywords: E3 ubiquitin ligase, MuRF1, muscle wasting, ubiquitin conjugating enzyme UBE2.